Journal of Clinical Oncology
Articles in this Issue
Reported side effects from treatment in a prospective phase II randomised trial evaluating local control after stereotactic body radiotherapy (SBRT) vs microwave ablation (MWA) in patients with colorectal liver metastases and oligometastatic disease.
e15522 Background: MWA is considered the treatment of choice for colorectal liver metastases in selected patients with small tumors and/or severe comorbid...
Epidemiology of plasma cell leukemia in the U.S.: Incidence, mortality and survival predictors.
e19579 Background: Plasma cell leukemia (PCL) is a rare and aggressive disorder with poor survival outcomes. It is defined by the presence of >20% circ...
Comparison of marking techniques for target lymph nodes in 2,596 patients with node-positive breast cancer treated with neoadjuvant chemotherapy: Results from the prospective multicenter AXSANA/EUBREAST-03/AGO-B-053 study (NCT04373655).
503 Background: Surgical axillary staging in patients with node-positive (cN+) breast cancer scheduled for neoadjuvant chemotherapy (NACT) varies signific...
Application of a novel multiplex imaging-based immunotherapy panel and AI-powered analysis solution for predictive spatial biomarker identification on immunotherapy-treated melanoma patients.
9524 Background: There is an urgent need for more robust methods to differentiate immunotherapy responders from non-responders. In this study, we present...
Patient-derived xenografts (PDX) versus patient-derived organoids (PDO) as predictors of clinical response to anti-cancer therapies.
e15169 Background: PDX and PDO are two of the most frequently applied avatar model systems used to predict treatment response to anti-cancer therapies. De...
Predictors of survival in advanced-stage, high grade primary peritoneal serous cystadenocarcinoma: An NCDB based analysis.
e16482 Background: High-grade primary peritoneal cystadenocarcinoma (HPPC) is a rare and aggressive malignancy originating from the peritoneal lining, fre...
Dalpiciclib plus chidamide in HR+/HER2- advanced breast cancer following CDK4/6 inhibitor treatment failure: Final results of a phase Ib trial.
e13071 Background: There is currently no standard treatment for patients with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (...
A global phase III, double-blind, randomized trial of BNT327/PM8002 plus chemotherapy (chemo) compared to atezolizumab plus chemo in patients (pts) with first-line (1L) extensive-stage small cell lung cancer (ES-SCLC).
TPS8129 Background: SCLC is an aggressive form of lung cancer. Incorporating immunotherapy for ES-SCLC pts in the frontline has improved outcomes, but lon...
Hospice discharges for 2022 among patients admitted for the most common malignancies: An analysis of the National Inpatient Sample.
e13557 Background: Hospice and home health care play significant roles in improving the quality of life and comfort for terminally ill patients. This anal...
Ziftomenib in relapsed/refractory (R/R) <i>NPM1</i> -mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study.
6506 Background: NPM1 -m drives leukemogenesis in ~30% of AML. Despite current risk stratification, nearly half will have R/R disease within a...
Right care, right place: Improving urgent care for breast cancer patients on chemotherapy.
e23229 Background: Breast cancer patients undergoing active chemotherapy frequently visit the Emergency Department (ED) with symptoms such as fever, pain,...
“The telehealth means I get distance from the hospital so I don’t feel so much like a patient”: A qualitative sub-study examining the acceptability of nurse-led follow-up for ovarian cancer via telehealth using the MOST-S26 to structure consultations.
12099 Background: The MOST-S26 is a patient-reported outcome measure that complements follow-up after first-line treatment for ovarian cancer (OC). MOST-S...
Efficacy and safety of disitamab vedotin combination therapy in HER2-positive advanced gynecological cancers: A multicenter retrospective analysis.
e17534 Background: Disitamab vedotin (RC48), an antibody-coupled drug, has demonstrated clinical benefits in HER2-expressing gynecological cancers. Howeve...
Landscape of geriatric oncology in Switzerland: Results from a nationwide survey.
e13855 Background: Geriatric oncology (GO) addresses the unique needs of older cancer patients, an increasingly critical population as the demographic shi...
Examining age-specific trends in the incidence of human papillomavirus-associated oropharyngeal cancer in the United States.
6081 Background: The incidence of human papillomavirus (HPV) infection-associated oropharyngeal cancer (OPC) has been steadily rising in the United States...
Balancing tumor control and toxicity: SBRT strategies for ultra-central NSCLC.
e20018 Background: Stereotactic body radiation therapy (SBRT) has shown exceptional efficacy for early-stage non-small cell lung cancer (NSCLC). However,...
A phase II study to evaluate the safety and efficacy of BB-1701 in subjects with HER2 expression locally advanced/metastatic breast cancer previously treated with HER2-ADC containing TOP-I inhibitor.
1093 Background: BB-1701 is an HER2-targeting antibody-drug conjugate (ADC) containing eribulin. In phase I study, BB-1701 had shown promising antitumor a...
Prediction of germline BRCA 1/2 genes pathogenetic variants from ultrasound images of healthy ovaries: Radiogenomics as an innovative tool to prevent BRCA-related cancers (PROBE II).
e17561 Background: BRCA 1/2 genes mutation identification enables women to opt for effective risk-reducing surgeries. Current indications for BRCA testing...
Neoadjuvant chemotherapy and surgery for rectal cancer: Omission of radiation in clinical practice.
3595 Background: PROSPECT proved efficacy of induction chemotherapy and surgery, without radiation, for select stage II and III rectal cancer patients wit...
Biomarkers associated with outcomes from OPTIMIZE-1: CD40 agonist mitazalimab with mFOLFIRINOX in patients with untreated metastatic pancreatic cancer.
2624 Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) has a 5-year overall survival (OS) rate of less than 5% and remains a leading cause o...
Analysis of knowledge gap regarding radiopharmaceuticals in patient communities.
e15134 Background: Radiopharmaceuticals are a rapidly evolving diagnostic and treatment field for cancer patients. One Cancer Place, Patient Advocates In...
Racial and socioeconomic disparities in testicular cancer survival outcomes: A SEER database analysis.
5028 Background: Testicular cancer, the most common malignancy in men aged 15 to 45 years, has a high cure rate exceeding 95% with early diagnosis and pro...
Decoding disparities: A SEER analysis of treatment patterns and timelines for orbital embryonal rhabdomyosarcoma across race, ethnicity, age, and geography (2000–2021).
e13795 Background: Orbital embryonal rhabdomyosarcoma (OER) is a rare skeletal muscle cancer in children. While studies have examined OER treatment progno...
Real-world data on the effectiveness and toxicity of CDK 4/6 inhibitors combined with hormonal therapy in patients with metastatic hormone receptor-positive and HER2-negative breast cancer in first- and second-line treatments within the Costa Rican health care system.
e13053 Background: Standard first- and second-line treatments for advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor...
Door-to-door oral cancer screening for 22,278 individuals (February 2020–April 2024): Breast Cancer Hub’s innovative grassroots approach addressing disparities and challenges in Assam’s underserved rural villages in India.
e13523 Background: Oral cancer remains a significant health issue in India, with the Northeast (NE) region showing notably higher rates, mainly due to wid...